Hemmingsen, M. G., Barzi, M., Chen, T., Collias, S., Beasley, J., Zhang, G., … Bissig, K. D. (2022). Validation of therapeutic strategies in a novel compound heterozygote model of Methylmalonic Acidemia. In HUMAN GENE THERAPY (Vol. 33, pp. A174–A174).

Hemmingsen, M. G., M. Barzi, T. Chen, S. Collias, J. Beasley, G. Zhang, Y. Ma, et al. “Validation of therapeutic strategies in a novel compound heterozygote model of Methylmalonic Acidemia.” In HUMAN GENE THERAPY, 33:A174–A174, 2022.

Hemmingsen MG, Barzi M, Chen T, Collias S, Beasley J, Zhang G, et al. Validation of therapeutic strategies in a novel compound heterozygote model of Methylmalonic Acidemia. In: HUMAN GENE THERAPY. 2022. p. A174–A174.

Hemmingsen, M. G., et al. “Validation of therapeutic strategies in a novel compound heterozygote model of Methylmalonic Acidemia.” HUMAN GENE THERAPY, vol. 33, no. 23–24, 2022, pp. A174–A174.

Hemmingsen MG, Barzi M, Chen T, Collias S, Beasley J, Zhang G, Ma Y, Ge K, Devlin G, Wu F, Gonzalez T, Rosales A, Young SP, Stiles A, El-Gharbawy A, Koeberl DD, Bissig-Choisat B, Chandler R, Asokan A, Newgard C, Venditti CP, Bissig KD. Validation of therapeutic strategies in a novel compound heterozygote model of Methylmalonic Acidemia. HUMAN GENE THERAPY. 2022. p. A174–A174.